Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK7 | P50613 | 6/20 | 0.57 |
| ▸ | CDK2 | P24941 | 5/20 | 0.57 |
| ▸ | AKT1 | P31749 | 5/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.45 |
| ▸ | CIT | O14578 | 1/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.44 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.44 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.44 |
| ▸ | WNT1 | P04628 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.41 |
| ▸ | GPR142 | Q7Z601 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4659680 | 0.92 | CDK2 (0.54) | CDK7CDK2AKT1ROCK1ROCK2 | |
| SCHEMBL4658449 | 0.91 | CDK2 (0.52) | CDK7CDK2AKT1ROCK1ROCK2 | |
| SCHEMBL4658636 | 0.90 | CDK7 (0.53) | CDK7CDK2AKT1ROCK1ROCK2 | |
| SCHEMBL5475633 | 0.85 | FGFR1 (0.49) | CDK7CDK2AKT1ROCK1FGFR1 | |
| SCHEMBL7068318 | 0.85 | CDK7 (0.76) | CDK7CDK2AKT1WNT1DYRK1A | |
| SCHEMBL6853364 | 0.85 | CDK7 (0.76) | CDK7CDK2AKT1WNT1DYRK1A | |
| SCHEMBL4722256 | 0.83 | AKT1 (0.54) | CDK2AKT1ROCK1FGFR1FGFR2 | |
| SCHEMBL4722252 | 0.83 | AKT1 (0.54) | CDK2AKT1ROCK1FGFR1FGFR2 | |
| SCHEMBL5478945 | 0.78 | FGFR2 (0.51) | AKT1ROCK1FGFR1FGFR2FGFR3 | |
| SCHEMBL5467086 | 0.78 | FGFR1 (0.52) | AKT1ROCK1FGFR1FGFR2FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1720855-A4 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORP (US) | 2008-12-17 | — | — | EP | claimed |
| US-20070185152-A1 | Inhibitors of akt activity | SMITHKLINE BEECHAM CORPORATION | 2007-08-09 | — | — | US | claimed |
| EP-1720855-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-15 | — | — | EP | claimed |
| WO-2005085227-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-15 | — | — | WO | claimed |
| EP-1720855-A4 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORP (US) | 2008-12-17 | — | — | EP | disclosed |
| US-20070185152-A1 | Inhibitors of akt activity | SMITHKLINE BEECHAM CORPORATION | 2007-08-09 | — | — | US | disclosed |
| EP-1720855-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005085227-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185152-A1 | Inhibitors of akt activity | AKT1, AKT1S1, AKT2 | CDK7 118/4885CDK2 44/4885AKT1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.